billS3033Event Wednesday, March 18, 2026Analyzed

Improving Access to Care for Rural Veterans Act

Bullish
Impact4/10

Summary

S.3033 mandates VA-rural hospital partnerships, creating revenue tailwinds for rural hospital operators ($HCA, $UHS) and healthcare staffing ($AMN) through mandatory co-location, leasing, and telehealth agreements. The bill is out of committee with bipartisan sponsorship but lacks funding authorization — actual impact requires future appropriations. Recent market data shows $AMN up 12.2% in 30 days, while $HCA and $UHS have declined sharply on separate sector pressures.

See which stocks are affected

Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.

Already have an account? Log in

Key Takeaways

  • 1.S.3033 mandates VA-rural hospital partnerships including co-location and leasing, creating structural revenue catalysts for rural hospital operators and staffing firms
  • 2.No funding is appropriated in the bill — execution depends on future budget allocations, adding uncertainty to revenue timing and magnitude
  • 3.$AMN (+12.2% in 30 days) has outperformed $HCA (-9.4%) and $UHS (-6.4%), suggesting the market is pricing staffing demand more immediately than hospital operating revenue
  • 4.Healthcare REITs $VTR (+6.8%) and $SBRA (+5.7%) benefit from potential VA leasing demand in medical office properties
  • 5.Bill still requires House passage and lacks companion bill — passage risk remains material

Market Implications

$AMN Healthcare ($20.58) has already absorbed the bill's staffing catalyst, trading near its 52-week high with strong 30-day momentum. Expect consolidation unless the bill reaches floor vote. $HCA ($428.9) and $UHS ($167.44) are under separate sector pressure — their 30-day declines of 9.4% and 6.4% respectively make the VA partnership catalyst a potential floor, not an upside driver. $VTR ($87.33) and $SBRA ($20.32) are at or near 52-week highs, with REIT tailwinds from stable rate expectations amplifying the bill's modest leasing catalyst. The market is pricing execution risk correctly given zero appropriated funds — only passage and subsequent appropriations will trigger meaningful revenue flows.

Full Analysis

The Improving Access to Care for Rural Veterans Act (S.3033) has cleared the Senate Veterans' Affairs Committee with a favorable report on March 18, 2026, and awaits floor action. The bill mandates every VA medical facility to enter into a partnership with a rural medical facility for co-location, space leasing, telehealth, training, care coordination, or emergency services. This is a structural mandate — VA facilities cannot opt out without a waiver capped at five years — meaning every rural hospital near a VA facility becomes a potential service delivery partner. The critical distinction: this bill authorizes a partnership mandate but appropriates ZERO dollars. The funding mechanism is entirely implicit — VA will pay for services and space out of existing appropriations or future VA medical care budgets. Without a specific funding stream, the mandate's execution pace depends on Secretary discretion and OMB budget allocation. The waiver provision allows the Secretary to delay compliance for up to five years per facility, creating execution risk. The market has diverged sharply across the affected tickers. $AMN Healthcare has rallied 12.21% over the past 30 days to $20.58, near its 52-week high of $23.74, likely pricing in the staffing demand signal. Meanwhile, $HCA has dropped 9.37% in 30 days and $UHS has fallen 6.44%, driven by broader hospital-sector headwinds — including the April 24 sell-off where $HCA dropped 8.8% in a single day — that overwhelmed any bill-specific catalyst. The healthcare REITs ($VTR +6.77%, $SBRA +5.67% over 30 days) show positive momentum, partially attributable to demand for medical office leasing. Next steps: S.3033 must pass the Senate floor, then the House (no companion bill yet introduced), then be signed into law. The 119th Congress is in its second session; with bipartisan sponsorship (Duckworth-D, Blackburn-R) and committee approval, passage probability is moderate but not guaranteed. Actual revenue impact to companies requires appropriations in FY2027 or later.

Intelligence Surface

Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures

Moderate

Some confirming evidence found across public data sources

Confirmed by:
$$HCA▲ Bullish
Est. $15.0M$75.0M revenue impact

What the bill does

mandated partnerships between VA medical facilities and rural medical facilities, requiring provision of co-location, leasing of space or equipment, care coordination, emergency services, or other services

Who must act

VA medical facilities (175+ nationwide), required to partner with all rural medical facilities in their catchment area

What happens

creates a direct revenue stream for rural hospital operators through VA patient referrals, co-location lease payments from VA occupying space, and fee-for-service agreements for emergency care and specialty services

Stock impact

$HCA operates the largest US hospital system with significant rural footprint (~30% of hospitals in non-urban areas); rural facility partnerships with VA directly increase patient volume and facility utilization without capital outlay, as VA pays for space and services

$$UHS▲ Bullish
Est. $5.0M$30.0M revenue impact

What the bill does

same mandated partnerships involving co-location, leasing of space or equipment, care coordination, emergency services

Who must act

VA medical facilities, required to partner with rural medical facilities including UHS acute care hospitals in rural regions

What happens

creates incremental patient volume and lease/co-location revenue for UHS rural hospital facilities

Stock impact

$UHS operates 135+ acute care hospitals, many in suburban/rural markets; VA partnership agreements shift uninsured VA patient care from uncompensated care to VA-reimbursed services, improving UHS payer mix

Market Impact Score

4/10
Minimal ImpactModerateMajor Market Event

Related Presidential Actions

Executive orders & memoranda affecting the same sectors or companies

Exec OrderApr 18, 2026

Accelerating Medical Treatments for Serious Mental Illness

This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.